Malignant peritoneal neoplasm

4 trials MedDRA PT
4 Registered trials
0 Recruiting
4 Unique sponsors
5 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 2
S Ophthalmology/ENT (ATC S) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Checkpoint inhibitor (PD-1) 1 substance
PARP inhibitor 1 substance
Corticosteroid 1 substance
Phase III: 1 Phase II: 1 Phase I: 1 Phase I (First in Human): 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • pharmaand GmbH Commercial
    NIVOLUMAB; RUCAPARIB
    2024-516662-11-00 11 countries 2018 n=257
    Ended

Phase II

1 trial
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic
    RUCAPARIB
    2024-516632-99-00 1 country 2021 n=300 Orphan
    Ended

Phase I

1 trial
  • Seagen Inc. Commercial
    IMP not specified
    2023-503389-22-00 4 countries 2022 n=147
    Ended

Phase I (First in Human)

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BRIMONIDINE TARTRATE; IMGN151; PREDNISOLONE ACETATE
    2023-506842-22-00 7 countries 2025 n=176
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 1 Phase I 0
pharmaand GmbH Commercial 1 Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I (First in Human) 0
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic 1 Phase II 0
New trials by year
2021
1
2022
1
2025
1
← All indication landscapes